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Abstract
Background: Brain lesions with a hypointense ring or core were described in multiple sclerosis on
susceptibility weighted imaging.
Objective: The purpose of this study was to study the evolution and prognostic relevance of susceptibility
weighted imaging hypointense lesions in clinically isolated syndrome and early multiple sclerosis.
Methods: Sixty-six early multiple sclerosis and clinically isolated syndrome patients were followed
over a median period of 2.9 years (range 1.6–4.6 years) and underwent 3T magnetic resonance imaging
including 3D susceptibility weighted imaging and T2-weighted fluid-attenuated inversion recovery. We
assessed the presence of susceptibility weighted imaging hypointense core or ring lesions, and Expanded
Disability Status Scale at baseline and follow-up.
Results: Of 611 lesions at baseline, 64 (10.5%) had a susceptibility weighted imaging hypointense core,
and 28 (4.6%) had a susceptibility weighted imaging hypointense ring. Hypointense ring lesions were
larger (p< 0.001) and more T1w hypointense (p¼ 0.002) than others. During follow-up, hypointense
core lesions became susceptibility weighted imaging isointense (52 lesions, 81%); few developed into
hypointense ring lesions (two lesions, 3%). Hypointense ring lesions did not shrink on T2-weighted
fluid-attenuated inversion recovery images (p¼ 0.077, trend towards more enlargement compared to
others), while hypointense core lesions more often shrunk in comparison to lesions without a hypo-
intense core (p¼ 0.002). The number of susceptibility weighted imaging hypointense ring lesions at
baseline correlated with Expanded Disability Status Scale progression at follow-up (p¼ 0.021,
R¼ 0.289).
Conclusion: In our cohort of patients with clinically isolated syndrome or early multiple sclerosis,
susceptibility weighted imaging hypointense ring lesions were only rarely detectable, but did not
shrink and were associated with future disability progression.
Keywords: Multiple sclerosis, clinically isolated syndrome, 3 Tesla MRI, ring sign, susceptibility
weighted imaging
Date received: 30 November 2019; accepted: 21 February 2020
Introduction
Multiple sclerosis (MS) is an inflammatory, demye-
linating and neurodegenerative central nervous
system disease with distinct brain lesions detectable
by magnetic resonance imaging (MRI).1,2 Recent
studies have identified different MS lesion types
based on their paramagnetic properties on gradient
echo MRI sequences such as susceptibility weighted
imaging (SWI).3–5 Most importantly, lesions
with a SWI hypointense core (‘core sign’), and
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lesions with a SWI hypointense ring (‘ring sign’)
were described.3–5
The pathophysiological correlates of those lesions
are not fully understood yet. In SWI hypointense
core lesions, severe demyelination or iron deposition
as a consequence of dying iron-rich oligodendro-
cytes or blood brain barrier breakdown with haemo-
globin leakage have been discussed as contributing
to SWI signal loss.5,6 Following this assumption, this
lesion type rather reflects a relatively young than an
old lesion.4,6–9
In SWI hypointense ring lesions, iron-rich active
microglia were histopathologically observed that
co-localise with the paramagnetic ring.10–15 The
‘ring sign’ was thus suggested as an in vivo imaging
feature of chronic active MS lesions that smoulder
over time and may contribute to disability progres-
sion in progressive MS disease stages.10–15
If these hypotheses hold true, SWI signal changes
may help to estimate the stage and chronic inflam-
matory activity of MS lesions, and potentially have
diagnostic, therapeutic and prognostic implications.
Nevertheless, current studies have predominantly
investigated lesion morphology and lesion evolution
in patients with long-lasting MS, and little is known
on the dynamics of SWI lesion morphology at the
very beginning of the disease when neuroinflamma-
tion is believed to outweigh neurodegeneration.
Based on this background, we aimed to describe the
presence of SWI hypointense core and ring lesions in
patients with clinically isolated syndrome (CIS) and
early MS. In addition, we asked whether SWI hypo-
intense core lesions at this very early stage of the
disease already develop into ring lesions, and wheth-
er the presence of such lesions at the beginning of
the disease are associated with clinical or paraclin-
ical worsening.
Methods
Study participants
Patients with CIS or relapsing–remitting MS as
defined by the 2010 diagnostic panel criteria1 were
included from the Berlin CIS cohort. The Berlin
cohort study of CIS and early MS (NCT01371071)
is an observational, prospective study that follows
patients over a period of at least 5 years to identify
risk factors for relapses, prognostic factors and ther-
apy response markers. Inclusion criteria are age
> 18 years, CIS within the last 6 months, and diag-
nosis of MS within the last two years. All patients
with a SWI scan at baseline, and a follow-up of at
least 18 months were eligible for this study.
Magnetic resonance (MR) images of insufficient
quality were excluded. Clinical disability was
assessed by the Expanded Disability Status Scale
(EDSS), the Symbol Digit Modalities Test (SDMT)
as a marker of cognitive function, and the Multiple
Sclerosis Functional Composite (MSFC) score
including the Nine-Hole Peg Test (9HPT), the
Timed 25-Foot Walk test (T25FWT) and the Paced
Auditory Serial Addition Test (PASAT). The study
was approved by the local ethics committee (EA1/
182/10). Written informed consent was obtained
from all participants before examination.
MRI acquisition
MR images were acquired using a 3T Siemens whole
body scanner (Trio TIM; Siemens, Erlangen,
Germany). The imaging protocol included pre- and
post-contrast three-dimensional T1*w magnetization
prepared rapid gradient echo (MPRAGE; spatial res-
olution¼ (1 11) mm3, gadolinium (0.1 mmol
Gd/kg) was used as contrast agent), and a three-
dimensional T2-weighted fluid-attenuated inversion
recovery (T2w-FLAIR; spatial resolution¼
(1 11) mm3). In addition, a three-dimensional
gradient echo flow-compensated SWI (echo time-
¼ 28 ms, repetition time¼ 35 ms, flip angle¼ 15,
spatial resolution¼ (1 11) mm3) yielding magni-
tude, filtered phase and reconstructed SWI images
was acquired (see Supplemental Material for more
details).
Image analysis
MRI scans were analysed by NB, EB (medical stu-
dents trained for the assessment of SWI lesion mor-
phology) and TS (resident in neurology with
experience in the analysis of gradient echo MR
images such as SWI) in consensus reading, and
blinded to clinical details. T2w-FLAIR hyperintense
lesions with a diameter of > 3 mm were marked.
Each T2w-FLAIR lesion was then looked up on
co-registered SWI to describe the existence of a
SWI hypointense core or a SWI hypointense ring
at the edge of the lesion at baseline.
A hypointense core was defined as homogenous dis-
tributed SWI hypointense signal intensity within the
centre of the lesion that is not related to a central
vein as identified by its tubular appearance and path-
way through the lesion edges. A hypointense ring
was defined as SWI hypointense signal intensity at
the edge of the lesion with rim-like appearance.
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Lesions with irregular SWI hypointense signal with-
out meeting the above criteria were characterised as
lesions with diffuse SWI hypointense signal. Lesions
without SWI hypointense signal were termed SWI
isointense.
Contrast enhancement was assessed on post-contrast
three-dimensional T1*w MPRAGE images.
Contrast-enhancing lesions with a SWI hypointense
ring were classified as ‘acute ring lesions’, and non-
contrast enhancing lesions with a SWI hypointense
ring were classified as ‘chronic ring lesions’.Next,
changes in lesion morphology were noted at follow-
up.
We also assessed lesion volume (change), percent-
age of brain volume change (PBVC),16 normalised
mean intralesional T1w signal intensity, contrast
enhancement, and the number of new lesions at
follow-up (see Supplemental Material for more
details).
Statistical analysis
All analyses were performed using IBM SPSS
Statistics (Version 20; IBM, Armonk, New York,
USA). All p values < 0.05 were considered signifi-
cant. Because of the exploratory nature of the study,
no adjustments for multiple comparisons were made.
Most of the variables were not normally distributed.
Thus, group differences were assessed by using a
nonparametric Mann–Whitney U test (MWU), and
we used Spearman correlation to test for associations
between imaging and clinical variables. Dichotomous
variables were compared by using Fisher’s exact test.
Finally, we used general linear models (GLMs) with
backward selection to assess the predictive value of
SWI imaging markers (p-to-exclude¼ 0.1). Results
were bootstrapped (resampling size n¼ 1000) and
confirmed by using Spearman correlation. PASAT,
T25FWT and 9HPT scores were transformed into z
scores. Relapse rates and PBVC were annualised.
Results
Study participants
Seventy-nine patients fulfilled the inclusion criteria,
and 13 patients were subsequently excluded for tech-
nical reasons (insufficient SWI image quality, see
also Supplemental Material Table 1 for missing
values). Finally, 66 patients with CIS (n¼ 32) or
relapsing–remitting MS (n¼ 34) were analysed and
followed over a median period of 2.9 years (range
1.6–4.6 years). More demographic details are pre-
sented in Table 1.
Lesion morphology at baseline
In total, we analysed 611 lesions at baseline. Of
these, 64 lesions (10.5%, mean standard deviation
(SD) per patient, range, 1.0 2.3, 0–12) had a SWI
hypointense core, 28 lesions had a SWI hypointense
ring (4.6%, mean SD per patient, range, 0.4 1.1,
0–6), and 19 lesions showed a diffuse SWI hypoin-
tense intralesional signal distribution (3.1%,
meanSD per patient, range, 0.3 0.8, 0–5). The
remaining 500 lesions (82%) were SWI isointense.
Hypointense ring lesions without contrast enhance-
ment were larger (p< 0.001) and had lower normal-
ised T1w intensity values (p< 0.001) in comparison
to lesions without a ring. The Supplemental Material
provides more information including a description of
the lesion morphology of gadolinium-enhancing
lesions.
The fate of SWI hypointense ring and core lesions
The ring sign persisted in 21 of all 28 ring lesions
(75%, Figure 1). In seven lesions, the ring sign dis-
appeared into SWI isointensity including all five
lesions with contrast enhancement at baseline
(‘acute ring sign’ lesions) as well as two others.
Lesions with and without hypointense rings at base-
line did not differ regarding change in normalised
T1w intensity values (MWU, p¼ 0.207) nor T2w-
FLAIR lesion volume (MWU, p¼ 0.077).
The hypointense core disappeared into SWI isointen-
sity in 52 of 64 lesions (81%, Figure 2), nearly dis-
appeared in two lesions (3%), and remained stable
in eight lesions (13%).
During follow-up, a distinct ring sign developed out
of two hypointense core (3%) and two diffuse hypo-
intense lesions (Figure 3). Two of them showed con-
trast enhancement at baseline.
Lesions with and without a hypointense core at base-
line did not differ regarding change in normalised
T1w intensity values nor T2w-FLAIR lesion volume
(all p< 0.290). Nonetheless, more hypointense core
lesions were classified as ‘shrinking’ in comparison
to lesions without a hypointense core (Figure 4,
Fisher’s exact test p¼ 0.002).
Group differences at baseline: MRI measures
Twenty patients (30%) had SWI hypointense core
lesions. We did not observe statistical significant
differences in age, gender, disease duration or
treatment between patients with and without SWI
hypointense core lesions (Table 1). Patients with
SWI hypointense core lesions had more T2w-FLAIR
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Table 1. Cohort overview and comparison between subgroups.
All patients
‘Ring sign’ ‘Core sign’
Yes No Yes No
Demographic data
n 66 13 53 28 38
Female (n) 40 7 33, p¼ 0.753 16 24, p¼ 0.799
Age (years), mean
SD, range
34 8.6, 20–52 34.9 9.8, 24–51 33.8 8.4, 20–52,
p¼ 0.921
35 8, 23–51 33.4 9, 20–52,
p¼ 0.375
Disease duration
(months), mean
SD, range
17.9 15.3, 0–52 23 16.4, 0–38 16.7 15, 0–52,
p¼ 0.191
20.6 16.1, 0–49 15.9 14.7, 1–52,
p¼ 0.380
Clinical and MRI findings at baseline
EDSS, median, range 1.5, 0–4.5 2, 0–3 1.5, 0–4.5,
p¼ 0.309
1.5, 0–3 1.5, 0–4.5,
p¼ 0.686
Total lesion count (n),
median, range
5, 0–45 18, 2–43 5, 0–45, p< 0.001 12, 3–45 3, 0–17, p< 0.001
Total lesion volume
(mm3), median,
range
330, 0–8626 2002, 268–7647 218, 0–8626,
p< 0.001
1464, 100–8626 113, 0–2168,
p< 0.001
Additional clinical measures at baseline
SDMT, median, range 61, 0–102 52, 0–68 64, 34–102,
p¼ 0.031
60, 0–102 62, 34–86,
p¼ 0.671
9HPT, median, range 18, 14–53 18, 15–53 18, 14–25,
p¼ 0.409
18, 14–53 18, 15–25,
p¼ 0.529
T25FWT, median,
range
4, 3–9 4, 3–5 4, 3–9, p¼ 0.419 4, 3–5 4, 3–9, p¼ 0.822
PASAT, median,
range
54, 0–60 57, 44–60 54, 0–60,
p¼ 0.136
57, 0–60 53, 19–60,
p¼ 0.091
Clinical and MRI findings at follow-up
Number of new
lesions (n), median,
range
0, 0–17 0, 0–5 0, 0–17, p¼ 0.885 0, 0–10 0, 0–17, p¼ 0.750
Annualised PBVC
(%), meanSD,
range
–0.24 0.47,
–2.33–0.43
–0.33 0.51,
–1.36–0.39
–0.22 0.46,
–2.33–0.43,
p¼ 0.453
–0.38 0.43,
–1.36–0.32
–0.14 0.48,
–2.33–0.43,
p¼ 0.008
Annualised relapse
rate, median, range
0, 0–1.8 0, 0–0.7 0, 0–1.8,
p¼ 0.201
0, 0–1.8 0, 0–0.6,
p¼ 0.851
EDSS, median, range 1.5, 0–5.5 2.5, 0–5.5 1, 0–5.5,
p¼ 0.010
1.5, 0–5.5 1, 0–5.5,
p¼ 0.094
Treatment
Treatment at baseline
(n, %)
No DMT: 36
(55%)
Platform: 23
(35%)
Oral: 7 (11%)
Infusion: 0
No DMT: 5 (38%)
Platform: 6 (46%)
Oral: 2 (15%)
Infusion: 0
No DMT: 31
(59%)
Platform: 17
(32%)
Oral: 5 (9%)
Infusion: 0
No DMT: 10
(36%)
Platform: 14
(50%)
Oral: 4 (14%)
Infusion: 0
No DMT: 26
(68%)
Platform: 9 (23%)
Oral: 3 (8%)
Infusion: 0
Treatment at follow-
up (n, %)
Unchanged: 44
(67%)
Switch to plat-
form: 6 (9%)
Switch to oral: 10
(15%)
Switch to infu-
sion: 6 (9%)
Unchanged:
8 (62%)
Switch to plat-
form: 0
Switch to oral: 4
(31%)
Switch to infu-
sion: 1 (8%)
Unchanged: 36
(68%)
Switch to plat-
form: 6 (11%)
Switch to oral: 6
(11%)
Switch to infu-
sion: 5 (9%)
Unchanged: 18
(64%)
Switch to plat-
form: 1 (4%)
Switch to oral: 4
(14%)
Switch to infu-
sion: 5 (18%)
Unchanged: 26
(68%)
Switch to plat-
form: 5 (13%)
Switch to oral: 6
(16%)
Switch to infu-
sion: 1 (3%)
9HPT: Nine-Hole Peg Test; EDSS: Expanded Disability Status Scale; MRI: magnetic resonance imaging; PASAT: Paced Auditory Serial
Addition Test; PBVC: percentage of brain volume change; SD: standard deviation; SDMT: Symbol Digit Modalities Test; T25FWT: Timed
25-Foot Walk test.
Values of p are related to a comparison between patients with and without ‘ring sign’ or ‘core sign’ lesions. Platform: treatment with glatiramer
acetate or beta-interferons. Oral: treatment with fingolimod, teriflunomide or dimethyl fumarate. Infusion: treatment with natalizumab or
alemtuzumab.
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lesions (MWU, p< 0.001, Table 1), higher lesion vol-
umes (MWU, p< 0.001, Table 1) and more contrast-
enhancing lesions (MWU, p¼ 0.022) at baseline.
Thirteen patients (19%) had SWI hypointense ring
lesions. We did not observe significant differences
in age, gender, disease duration or treatment between
patients with and without SWI hypointense ring
lesions (Table 1). Patients with SWI hypointense
ring lesions had more T2w-FLAIR lesions
(MWU, p< 0.001), higher lesion volumes (MWU,
p< 0.001), more contrast enhancing lesions (MWU,
p¼ 0.002) and overall lower normalised intralesional
T1w signal intensity values (MWU, p¼ 0.014) at
baseline (see Supplemental Material for more details).
Group differences at baseline: clinical parameters
Patients with SWI hypointense core or ring lesions,
did not differ regarding clinical measures including
sex, age, disease duration, EDSS, MSFC, 9HPT,
T25FWT and PASAT (all p> 0.091, Table 1)
except for patients with SWI hypointense ring lesions
who had lower SDMT values (MWU, p¼ 0.031, see
Supplemental Material for more details).
Predictive value of SWI markers at baseline:
MRI measures
A higher number of SWI hypointense core lesions per
patient at baseline correlated with higher rates of brain
volume loss during follow-up (PBVC, Spearman,
p< 0.001, rho¼ –0.424), but did not predict the
number of new lesions or the degree of mean normal-
ised T1w signal intensity at follow-up (all p> 0.924,
Table 1, see Supplemental Material for more details).
The number of SWI hypointense ring lesions at base-
line did not predict the degree of brain atrophy
during follow-up, the number of new lesions or the
degree of mean normalised T1w signal intensity at
follow-up (all p> 0.126, Table 1, see Supplemental
Material for more details).
The analysis of the proportion of lesions with a SWI
hypointense core or ring instead of the number of
Figure 1. The fate of an exemplary ‘ring sign’ lesion.
Susceptibility weighted imaging (SWI; top) and T2 weighted fluid attenuated inversion recovery (T2w-FLAIR; bottom)
images are shown at baseline (left) and follow-up (right). At baseline, a prominent hyperintense white matter lesion is
visualised on T2w-FLAIR. The lesion is characterised by a SWI hypointense signal at the edge of the lesion (‘ring sign’).
During follow-up, the appearance of the lesion on SWI and T2w-FLAIR does not change significantly. The ‘ring sign’ is
still clearly visible, and the size of the lesion has not clearly changed. BL: baseline; FU: follow-up.
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lesions did not significantly change the results (data
not presented).
Predictive value of SWI markers at baseline:
clinical parameters
An EDSS increase was observed in 17 patients
(26%). Patients with SWI hypointense ring lesions
had higher EDSS values at follow-up (MWU,
p¼ 0.010, Table 1) and showed a higher EDSS
increase (MWU, p¼ 0.032, Figure 5). In addition,
the number of SWI hypointense ring lesions per
patient correlated with higher EDSS values at
follow-up (Spearman, p¼ 0.005, rho¼ 0.342), and
EDSS change (Spearman, p¼ 0.021, rho¼ 0.289).
By using a general linear model with backward
selection and EDSS at follow-up as the dependent
variable, and sex, age, disease duration, disease
course, EDSS at baseline, lesion count, lesion
volume, number of contrast enhancing lesions and
SWI hypointense ring/core lesions as independent
variables, only age (B¼ 0.029, p¼ 0.042), EDSS
at baseline (B¼ 0.723, p< 0.001) and the number
of SWI hypointense ring lesions at baseline
(B¼ 0.371, p¼ 0.001) remained significant within
the model (R2¼ 0.587, p< 0.001) and thus were pre-
dictive for the EDSS at follow-up (see Supplemental
Material for more analyses that better illustrate that
this association is independent of the overall T2w-
FLAIR lesion load). The results were confirmed by
bootstrapping.
We did not observe an association between the
number of SWI hypointense core or ring lesions
and any other clinical measures at follow-up includ-
ing EDSS (hypointense core lesions), number of
relapses, conversion from CIS to RRMS, MSFC,
9HPT, T25FWT, PASAT and SDMT (all
p> 0.250). Accordingly, patients with SWI hypoin-
tense core lesions and patients with SWI hypointense
ring lesions did not differ from patients without such
lesions regarding these clinical outcome measures
(all p> 0.094, Table 1).
The analysis of the proportion of lesions with a SWI
hypointense core or ring instead of the number of
lesions did not significantly change the results (data
not presented).
Discussion
In this study we have investigated the temporal evo-
lution of SWI hypointense ring and core lesions in a
rather young early MS and CIS cohort to assess the
prognostic relevance of these novel MRI biomarkers
at the very beginning of the disease.
We observed that only a relatively small proportion
of patients within our cohort had hypointense ring
lesions while more patients had hypointense core
lesions. Patients with either hypointense ring or
core lesions had more T2w-FLAIR lesions at base-
line. During follow-up, the majority of hypointense
core lesions became SWI isointense and/or shrunk.
Few hypointense core lesions developed into hypo-
intense ring lesions. Hypointense ring lesions did not
shrink, and only sporadic become SWI isointense
over time. Finally, patients with SWI hypointense
ring lesions at baseline had a more severe EDSS
progression than patients without.
SWI is a gradient echo imaging technique that is
sensitive to changes of the magnetic field on the
Figure 2. The fate of an exemplary ‘core sign’ lesion
without contrast enhancement.
Susceptibility weighted imaging (SWI; top) and T2
weighted fluid attenuated inversion recovery (T2w-
FLAIR; bottom) images are shown at baseline (left) and
follow-up (right). At baseline, a hyperintense white matter
lesion is visualised on T2w-FLAIR. The lesion is charac-
terised by a SWI hypointense signal within the centre of
the lesion (‘core sign’). During follow-up, the lesion
became smaller on T2w-FLAIR, and the SWI hypointense
signal (‘core sign’) disappeared rendering the lesion iso-
intense to slightly hyperintense on SWI. BL: baseline; FU:
follow-up.
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microscopic level.11,17 Thus, the presence of para-
magnetic substances and changes in the magnetic
microstructure of the tissue will lead to signal
changes on SWI.17 This makes SWI – and other
gradient echo MR imaging techniques such as
T2*w imaging and quantitative susceptibility map-
ping (QSM) – an attractive imaging technique
to explore new imaging biomarkers as it provides
additional information on top of conventional
MR measures.
In MS, different imaging patterns were described on
SWI.18,19 In a varying proportion of MS lesions, a
distinct SWI hypointense core can be visual-
ised.3,5,20,21 The pathophysiological correlate of
this imaging finding is not fully understood, but
our data show that the SWI hypointense core does
not resemble T1w hypointense lesions. One hypoth-
esis is that the SWI hypointense core is either the
consequence of a loss of diamagnetic myelin
because of severe demyelination or paramagnetic
iron deposits.5,20,22 But where does the iron come
from? Oligodendrocytes are by far the predominant
iron-containing cells in the brain as they carry iron-
requiring enzymes necessary for myelin produc-
tion.23 Intra-lesional iron deposits may thus be the
consequence of dying oligodendrocytes releasing
iron into the extracellular space, or reflect an
increased iron-demand of oligodendrocytes during
re-myelination.23–25 Another idea is that intra-
lesional iron deposits derive from leaky blood ves-
sels within the MS lesions as a consequence of blood
brain barrier (BBB) breakdown.20,22 The observation
that many young MS lesions with a nodular contrast
enhancement as a sign of BBB breakdown are QSM
negative, however, argues against this hypothe-
sis.9,26,27 In any case, all these assumptions suggest
that a SWI hypointense core is a sign of disease
activity and/or subsequent early repair mechanisms
and thus probably reflect an imaging feature of
Figure 3. Transition of a ‘core sign’ lesion into a ‘ring sign’ lesion.
Susceptibility weighted imaging (SWI; top) and T2 weighted fluid attenuated inversion recovery (T2w-FLAIR; bottom)
images are shown at baseline (left) and follow-up (right). At baseline, a prominent hyperintense white matter lesion is
visualised on T2w-FLAIR (red arrow). The lesion is characterised by a SWI hypointense signal within the centre of the
lesion (‘core sign’). During follow-up, the appearance of the lesion on SWI changes. The ‘core sign’ is not visible
anymore, but a distinct SWI hypointense ring (‘ring sign’) has been formed. Also, a vein is now visible within the centre
of the lesion (‘central vein sign’ indicated by the black dot within the lesion centre as the vein runs perpendicular to the
image plane) that was previously ‘covered’ by the ‘core sign’. Also note the ‘ring sign’ lesion that is already visible at
baseline (yellow arrow), which did not change its size or morphology during follow-up (yellow arrow). BL: baseline; FU:
follow-up.
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Figure 4. The fate of an exemplary contrast enhancing ‘core sign’ lesion.
The figure illustrates susceptibility weighted imaging (SWI; top) and T2 weighted fluid attenuated inversion recovery
(T2w-FLAIR; bottom) images at baseline (left) and follow-up (right). At baseline, a subcortical hyperintense white matter
lesion is visualised on T2w-FLAIR. The lesion shows contrast enhancement (yellow arrow) and exhibits a SWI hypo-
intense signal within the centre of the lesion (‘core sign’). During follow-up, the lesion became smaller on T2w-FLAIR,
and the SWI hypointense signal (‘core sign’) disappeared rendering the lesion slightly hyperintense on SWI. BL: baseline;
FU: follow-up.
Figure 5. Boxplots.
Boxplots on group differences in Expanded Disability Status Scale (EDSS) at follow-up (left) and EDSS change (right) between patients with and
without ‘ring sign’ lesions at baseline are displayed. Patients with ‘ring sign’ lesions at baseline had higher EDSS values at follow-up (left,
p¼0.010) and showed a higher change in EDSS (right, p¼0.032).
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rather younger than older MS lesions.6,7 Our results
strongly support this hypothesis as a relevant propor-
tion of SWI hypointense core lesions shrunk or
became SWI isointense over time. Also, a decrease
in magnetic susceptibility over time was described in
MS lesions7 and paramagnetic MR signal changes
were more often observed in MS patients with a
short versus long disease duration.6 Both observa-
tions are in good agreement with our results. The
‘young lesion hypothesis’ of SWI hypointense core
lesions may also explain the association between the
latter and higher T2w-FLAIR lesion counts or
increased rates of future brain atrophy as a conse-
quence of Wallerian degeneration. Please note that
the statistical analysis remained inconclusive wheth-
er brain atrophy was indeed predicted by SWI hypo-
intense core lesions as SWI hypointense core lesions
and T2w-FLAIR lesion counts were intercorrelated.
In addition, acute and chronic paramagnetic or SWI
hypointense rings (‘ring sign’) were described
around a proportion of MS lesions.10–15 Acute
rings are rather thin and typically co-localise with
the area of contrast enhancement in ring enhancing
MS lesions.28 They are likely to reflect spreading
inflammatory activity including higher concentra-
tions of proteins at the lesion edges, rather than
iron deposition.28 Our data is well in line with this
hypothesis as most SWI hypointense rings around
contrast enhancing lesions disappeared over time
suggesting that this is a rather transient feature of
acute MS lesions. In contrast, chronic rings are more
prominent or thick on gradient echo images28 and
were shown to persist over a longer period of
time.4,12,29 Histopathological and PET data suggest
that the SWI hypointense ring corresponds to iron
within CD68 positive cells such as microglia or mac-
rophages at the edge of (chronic) active MS
lesions.10–15 One hypothesis is that microglia and/
or macrophages incorporate and redistribute the
iron from the centre of the lesion to the edge
during lesion development as iron sequestration by
macrophages is an important inflammatory
response.30 This idea is further supported by a
recent experimental study showing that iron induces
M1 polarization of macrophages and that iron uptake
is regulated by proinflammatory cytokines.30
Our data is well in line with this hypothesis as
we - for the best of our knowledge – for the first
time visualised the development of a SWI hypoin-
tense ring out of a SWI hypointense core lesion in
vivo, which might indicate a redistribution of iron as
discussed above.
Following the idea of the ‘ring sign’ as an in vivo
biomarker of chronic active MS lesions, different
research groups have investigated whether the ‘ring
sign’ is a feature of smoldering or slowly enlarging
lesions and whether the presence of ‘ring sign’
lesions is associated with a worse clinical out-
come.6,12,16-19,31-35 While some studies have indeed
described an association of the ‘ring sign’ with pro-
gressive MS,33 higher levels of clinical disabili-
ty17,33 and smoldering lesions,12,31 others did not
observe such relationships.6,16,32,34,35 These discrep-
ancies are likely to be the consequence of different
study populations, sample sizes and follow-up inter-
vals. A long follow-up is of high relevance, as the
lesions grow with a rate of less than 1 mm per
year.12 Our data, which includes a follow-up of up
to 4.6 years did not show an enlargement of ‘ring
sign’ lesions over time, but in contrast to ‘core sign’
lesions, ‘ring sign’ lesions did not shrink and showed
a trend towards more enlargement compared to other
lesions. Hence, it remains inconclusive whether the
‘ring sign’ is indeed a marker of slowly enlarging
lesions.
Nevertheless, the existence of ‘ring sign’ lesions at
baseline was associated with the degree of disability
as measured by EDSS and SDMT as well as disabil-
ity worsening at follow-up as measured by (change
in) EDSS. This supports the idea that patients with
‘ring sign’ lesions are somehow characterised by a
proinflammatory stage.12,13,31 The magnitude of this
association was, however, only moderate, and we
did not observe an association with additional
markers of disease progression, which suggest that
other (unknown) factors significantly contribute to
disability progression in CIS and early MS.
Our study is not free of limitations. Although we
followed all participants over a median period of
2.9 years, this follow-up could still be too short in
order to detect relatively small volume changes
within slowly expanding lesions. A much longer
follow-up interval is probably needed to fully under-
stand the evolution of ring lesions in terms of size
and SWI signal intensity. Also, study participants
were treated with a mix of different disease modify-
ing therapies. Although we did not observe clear
differences in lesion morphology between treatment
groups, the number of study participants within sub-
groups was limited, and the potential treatment
effect of disease modifying therapies on the devel-
opment of ring sign lesions remains largely
unknown. Finally, the overall degree of disease
activity was relatively low in this cohort, which
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may have reduced the power in detecting associa-
tions between SWI image characteristics and clinical
outcome measures including cognitive function.
In conclusion, hypointense core lesions were fre-
quently detectable in patients with CIS or early
MS and are likely to reflect early MS lesion stages
as most of them become SWI isointense over time.
In our CIS and early MS cohort, only few hypoin-
tense core developed into hypointense ring lesions,
and hypointense ring lesions were only rarely detect-
able at all. If present, they were associated with
future disability progression, which renders them
interesting for future clinical trials and personalised
health directed approaches.
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